Susquehanna International Group’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $40.6M | Sell |
122,800
-163,400
| -57% | -$55.6M | ﹤0.01% | 1455 |
|
|
2025
Q4 | $114M | Sell |
286,200
-47,700
| -14% | -$21.1M | 0.01% | 808 |
|
|
2025
Q3 | $152M | Buy |
333,900
+160,400
| +92% | +$65.3M | 0.02% | 655 |
|
|
2025
Q2 | $56.6M | Sell |
173,500
-45,500
| -21% | -$12.6M | 0.01% | 1081 |
|
|
2025
Q1 | $59.1M | Buy |
219,000
+55,700
| +34% | +$14.3M | 0.01% | 933 |
|
|
2024
Q4 | $38.4M | Sell |
163,300
-121,800
| -43% | -$32M | 0.01% | 1312 |
|
|
2024
Q3 | $78.4M | Sell |
285,100
-154,700
| -35% | -$40.3M | 0.01% | 790 |
|
|
2024
Q2 | $107M | Buy |
439,800
+7,000
| +2% | +$1.11M | 0.02% | 573 |
|
|
2024
Q1 | $64.7M | Buy |
432,800
+29,600
| +7% | +$4.94M | 0.01% | 881 |
|
|
2023
Q4 | $77.2M | Buy |
403,200
+27,000
| +7% | +$4.6M | 0.01% | 805 |
|
|
2023
Q3 | $66.6M | Buy |
376,200
+166,400
| +79% | +$31.7M | 0.01% | 827 |
|
|
2023
Q2 | $39.8M | Buy |
209,800
+10,300
| +5% | +$2.04M | 0.01% | 1154 |
|
|
2023
Q1 | $40M | Sell |
199,500
-37,300
| -16% | -$7.84M | 0.01% | 1094 |
|
|
2022
Q4 | $56.3M | Buy |
236,800
+65,700
| +38% | +$14M | 0.01% | 820 |
|
|
2022
Q3 | $34.2M | Sell |
171,100
-256,800
| -60% | -$49M | 0.01% | 1031 |
|
|
2022
Q2 | $62.4M | Buy |
427,900
+121,000
| +39% | +$17.2M | 0.02% | 728 |
|
|
2022
Q1 | $50.1M | Buy |
306,900
+64,200
| +26% | +$9.78M | 0.01% | 1005 |
|
|
2021
Q4 | $41.2M | Buy |
242,700
+88,900
| +58% | +$16.5M | 0.01% | 1239 |
|
|
2021
Q3 | $29M | Sell |
153,800
-75,800
| -33% | -$14.2M | ﹤0.01% | 1622 |
|
|
2021
Q2 | $38.9M | Buy |
229,600
+128,400
| +127% | +$18.8M | 0.01% | 1389 |
|
|
2021
Q1 | $14.3M | Sell |
101,200
-148,800
| -60% | -$22.4M | ﹤0.01% | 2294 |
|
|
2020
Q4 | $32.5M | Buy |
250,000
+67,200
| +37% | +$8.97M | 0.01% | 1307 |
|
|
2020
Q3 | $26.6M | Buy |
182,800
+39,300
| +27% | +$5.58M | 0.01% | 1252 |
|
|
2020
Q2 | $21.3M | Sell |
143,500
-173,000
| -55% | -$23.3M | 0.01% | 1374 |
|
|
2020
Q1 | $34.5M | Sell |
316,500
-91,500
| -22% | -$10.6M | 0.01% | 846 |
|
|
2019
Q4 | $47M | Buy |
408,000
+108,100
| +36% | +$10.8M | 0.01% | 847 |
|
|
2019
Q3 | $24.1M | Buy |
299,900
+33,500
| +13% | +$2.65M | 0.01% | 1200 |
|
|
2019
Q2 | $19.3M | Buy |
266,400
+64,200
| +32% | +$4.93M | 0.01% | 1309 |
|
|
2019
Q1 | $18.9M | Sell |
202,200
-112,500
| -36% | -$9.41M | 0.01% | 1244 |
|
|
2018
Q4 | $22.9M | Buy |
314,700
+1,800
| +0.6% | +$138K | 0.01% | 989 |
|
|
2018
Q3 | $27.4M | Buy |
312,900
+141,300
| +82% | +$14.2M | 0.01% | 1080 |
|
|
2018
Q2 | $16.9M | Sell |
171,600
-29,700
| -15% | -$2.95M | 0.01% | 1433 |
|
|
2018
Q1 | $24M | Sell |
201,300
-196,700
| -49% | -$25.4M | 0.01% | 1092 |
|
|
2017
Q4 | $50.6M | Sell |
398,000
-314,600
| -44% | -$39.5M | 0.02% | 686 |
|
|
2017
Q3 | $83.7M | Buy |
712,600
+398,400
| +127% | +$34M | 0.03% | 454 |
|
|
2017
Q2 | $25.1M | Buy |
314,200
+24,100
| +8% | +$1.54M | 0.01% | 990 |
|
|
2017
Q1 | $14.9M | Sell |
290,100
-143,000
| -33% | -$6.61M | 0.01% | 1297 |
|
|
2016
Q4 | $16.2M | Buy |
433,100
+209,900
| +94% | +$8.79M | 0.01% | 1199 |
|
|
2016
Q3 | $15.1M | Buy |
223,200
+64,400
| +41% | +$4.54M | 0.01% | 1220 |
|
|
2016
Q2 | $8.81M | Sell |
158,800
-221,100
| -58% | -$13.9M | ﹤0.01% | 1561 |
|
|
2016
Q1 | $23.8M | Buy |
379,900
+283,800
| +295% | +$18.9M | 0.01% | 886 |
|
|
2015
Q4 | $9.05M | Sell |
96,100
-160,900
| -63% | -$14.9M | ﹤0.01% | 1857 |
|
|
2015
Q3 | $20.7M | Buy |
257,000
+54,700
| +27% | +$6.08M | 0.01% | 1173 |
|
|
2015
Q2 | $24.3M | Sell |
202,300
-14,300
| -7% | -$1.71M | 0.01% | 1137 |
|
|
2015
Q1 | $22.6M | Buy |
216,600
+106,000
| +96% | +$10.7M | 0.01% | 1143 |
|
|
2014
Q4 | $10.7M | Sell |
110,600
-110,600
| -50% | -$10.2M | ﹤0.01% | 1958 |
|
|
2014
Q3 | $17.3M | Buy |
221,200
+111,300
| +101% | +$7.18M | 0.01% | 1557 |
|
|
2014
Q2 | $6.94M | Buy |
109,900
+14,700
| +15% | +$874K | ﹤0.01% | 2580 |
|
|
2014
Q1 | $6.39M | Buy |
95,200
+13,900
| +17% | +$1.08M | ﹤0.01% | 2556 |
|
|
2013
Q4 | $5.23M | Buy |
81,300
+20,800
| +34% | +$1.24M | ﹤0.01% | 2889 |
|
|
2013
Q3 | $3.87M | Buy |
60,500
+46,700
| +338% | +$2.33M | ﹤0.01% | 3090 |
|
|
2013
Q2 | $428K | Buy |
+13,800
| New | +$367K | ﹤0.01% | 6280 |
|
Other funds holding ALNY
VPM
VCM
Susquehanna International Group's ALNY Position: Q1 2026 in Review
Susquehanna International Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 9.2% in Q1 2026, selling an estimated $5.97M and leaving 174,268 shares worth $57.7M. The position accounts for 0.01% of the portfolio, ranked #1182.
Susquehanna International Group first reported a position in ALNY in Q3 2013 and has held it in 49 quarters since. The position peaked at $263M in Q3 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Susquehanna International Group held 174,268 shares of Alnylam Pharmaceuticals worth $57.7M as of Q1 2026.
- Susquehanna International Group sold 17,552 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $5.97M.
- Alnylam Pharmaceuticals made up 0.01% of Susquehanna International Group's portfolio in Q1 2026, its #1182 holding.
- Susquehanna International Group first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 49 quarters since.
- Susquehanna International Group's Alnylam Pharmaceuticals position peaked at $263M in Q3 2025.
- 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.